Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities
Primary Purpose
Peripheral Vascular Disease
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
GRST Peripheral Catheter System
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Vascular Disease
Eligibility Criteria
Inclusion Criteria:
- Patient is ≥18 years of age
- Patient is Rutherford category 2-4
- De novo lesion in the SFA or popliteal artery with a diameter stenosis ≥50%
- Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of <99%
- Target lesion stenosis has a length of ≤100 mm based on visual assessment
- Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment
- Angiographic evidence of distal runoff defined as minimum one (1) patent tibial artery with a straight flow to the foot
- Patient is willing and able to provide written informed consent prior to any study specific procedure
- Patient is willing and able to comply with specified follow-up evaluations at the specified times
Exclusion Criteria:
- Any prior intervention in the intended target lesion including 10 mm proximal or distal from the intended treatment area
- Evidence of thrombus in the target vessel
- Prior ipsilateral or contralateral lower limb arterial bypass
- Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure
- Target lesion is severely calcified
- Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).
- Any planned surgery within 30 days of the study procedure.
- Renal failure (serum creatinine > 2.0 mg/dL)
- Female with childbearing potential without a negative pregnancy test
- Patient has had an organ transplant
- Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study
- In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
GRST Peripheral Catheter System
Outcomes
Primary Outcome Measures
Major adverse clinical events rate
Secondary Outcome Measures
Binary restenosis
Target lesion revascularization
Amputation rate
Technical success
Serious adverse events rate, including major adverse clinical events
Full Information
NCT ID
NCT00751283
First Posted
September 9, 2008
Last Updated
August 12, 2013
Sponsor
Vessix Vascular, Inc
1. Study Identification
Unique Protocol Identification Number
NCT00751283
Brief Title
Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities
Official Title
Minnow Medical GRST Peripheral Catheter System First-in-Man Study Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Withdrawn
Why Stopped
Data was inconclusive
Study Start Date
August 2007 (undefined)
Primary Completion Date
November 2010 (Actual)
Study Completion Date
May 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vessix Vascular, Inc
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of the Minnow Medical GRST Peripheral Catheter System in the treatment of new lesions in the superficial femoral artery or the popliteal artery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Vascular Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
GRST Peripheral Catheter System
Intervention Type
Device
Intervention Name(s)
GRST Peripheral Catheter System
Intervention Description
Treatment to dilate stenoses and reduce plaque in treated vessels
Primary Outcome Measure Information:
Title
Major adverse clinical events rate
Time Frame
Up to 30 days
Secondary Outcome Measure Information:
Title
Binary restenosis
Time Frame
30 days, 3 months, 6 months
Title
Target lesion revascularization
Time Frame
30 days, 3 months, 6 months
Title
Amputation rate
Time Frame
30 days, 3 months, 6 months
Title
Technical success
Time Frame
Treatment
Title
Serious adverse events rate, including major adverse clinical events
Time Frame
30 days, 3 months, 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is ≥18 years of age
Patient is Rutherford category 2-4
De novo lesion in the SFA or popliteal artery with a diameter stenosis ≥50%
Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of <99%
Target lesion stenosis has a length of ≤100 mm based on visual assessment
Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment
Angiographic evidence of distal runoff defined as minimum one (1) patent tibial artery with a straight flow to the foot
Patient is willing and able to provide written informed consent prior to any study specific procedure
Patient is willing and able to comply with specified follow-up evaluations at the specified times
Exclusion Criteria:
Any prior intervention in the intended target lesion including 10 mm proximal or distal from the intended treatment area
Evidence of thrombus in the target vessel
Prior ipsilateral or contralateral lower limb arterial bypass
Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure
Target lesion is severely calcified
Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).
Any planned surgery within 30 days of the study procedure.
Renal failure (serum creatinine > 2.0 mg/dL)
Female with childbearing potential without a negative pregnancy test
Patient has had an organ transplant
Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study
In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dierk Scheinert, MD
Organizational Affiliation
Universität Leipzig Herzzentrum
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities
We'll reach out to this number within 24 hrs